Egypt

Egypt has no population‑wide dementia screening programme. Detection is largely opportunistic, occurring in primary care when cognitive symptoms become functionally disruptive, and systematic within hospital‑based memory clinics. Psychiatry and geriatrics units routinely use brief cognitive screening tools, such as the Mini‑Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) equivalents, and functional scales, complemented by clinical history and carer interviews.

Computed tomography (CT) and magnetic resonance imaging (MRI) are standard components of dementia work‑ups and are widely available in university hospitals and large private centres. These modalities underpin most diagnoses, particularly in distinguishing vascular and mixed dementias. Advanced molecular imaging exists in Cairo’s private sector, including positron emission tomography (PET) and PET/MRI, but amyloid‑PET is not routine and is used selectively due to cost, limited clinical integration, and lack of reimbursement within the public pathway.

Genetic testing is not part of routine dementia diagnostics in Egypt and is not included in national clinical guidelines or the standard public care pathway. Common risk genotyping such as APOE ε4 is generally considered to have limited clinical utility for routine diagnosis and is therefore not used in day-to-day practice within public hospitals. This approach aligns with prevailing norms in many middle‑income health systems, where genetic information is not viewed as actionable in the absence of disease‑modifying therapies.

In exceptional cases, notably very early‑onset dementia (typically <65 years) or strong multigenerational family history suggesting a monogenic form of Alzheimer’s disease, genetic testing may be pursued outside the public pathway. Such testing is usually arranged through private laboratories, international diagnostic providers, or research‑linked university collaborations, rather than through UHI‑covered services. As a result, access depends heavily on financial capacity, clinician networks, and academic affiliation, and results are more often used for diagnostic clarification or research purposes than for direct changes in management.

Biomarker‑based diagnosis is not yet embedded in Egypt’s routine dementia pathway. While cerebrospinal fluid (CSF) biomarkers, including amyloid‑β (Aβ42/40), total tau, and phosphorylated tau, are internationally recognised, there is no documented evidence of their systematic use in Egypt’s public‑sector memory services.

Mental health services are overseen by the General Secretariat of Mental Health and Addiction Treatment (GSMHAT), which operates a limited network of hospitals and outpatient clinics and serves a population of over 100 million with approximately 1,100 psychiatrists, resulting in low provider-to-population ratios. Services are fragmented across different ministerial and university systems, leading to weak coordination and uneven care pathways. While psychogeriatric units exist in a small number of university hospitals, geriatric psychiatry capacity remains scarce, psychiatric bed availability is low, and services are heavily urban-concentrated, leaving many rural areas underserved. Integration of mental health into primary care is limited, and despite rights-based reforms under the 2009 Mental Health Act, implementation, particularly for older adults, remains inconsistent, leaving families and GPs to shoulder much of the care load.

Specialised dementia, memory, and geriatric services in Egypt are highly concentrated in university and teaching hospitals, which function as the core providers of diagnosis, treatment planning, and specialist follow-up. Ain Shams University’s geriatrics services, including Ahmad Shawky Geriatrics Hospital, and Cairo University’s old-age psychiatry and memory clinic are among the most prominent national reference centres, drawing referrals from across multiple governorates. These institutions typically offer multidisciplinary assessment (geriatrics, neurology, psychiatry, radiology), access to CT and MRI, and exposure to internationally aligned clinical practices.

National Institute for Longevity Elderly Sciences (NILES) at Beni-Suef University and geriatric units at major universities such as Alexandria, Tanta, Mansoura and Cairo, with additional access through private hospitals like Behman Hospital. Memory clinics and cognitive stimulation therapy (CST) are gradually emerging, supported by research and culturally adapted implementation led by Cairo University and demonstrated community benefits in Mansoura, but services remain geographically concentrated in academic and private centres, limiting access for older adults in rural areas and smaller cities who often must travel long distances for assessment and follow-up.

Palliative care capacity exists in Egypt and has expanded in recent years, largely through cancer and hospital-based programmes. However, its integration into routine dementia and non-cancer neurodegenerative pathways remains limited, reflecting broader regional patterns addressed through World Health Organization Regional Office for the Eastern Mediterranean (WHO-EMRO) initiatives on palliative care development.

Under the phased implementation of UHI, follow-up specialist visits, basic monitoring, and symptomatic dementia medications are covered when delivered through contracted public providers. However, coverage depth and co-payment requirements vary by governorate and stage of rollout, leading to inconsistent patient experiences across the country. Services accessed outside the contracted public network, including private consultations, private imaging, non-covered medications, or advanced diagnostics, are paid out-of-pocket. Beyond direct medical costs, families frequently incur substantial indirect expenses, including transportation to tertiary hospitals, hiring paid carers, and accessing private rehabilitation or cognitive therapy services when public options are unavailable or insufficient.

Caregiver support in Egypt is predominantly NGO-led rather than state-institutionalised. Family care partners form the backbone of dementia care in Egypt, providing most daily assistance without formal training or systemic support and experiencing substantial psychological and emotional strain as a result. Studies consistently show moderate to severe carer load, high levels of anxiety and depression, and reduced quality of life, particularly among women, who disproportionately shoulder caregiving responsibilities, while evidence from hospital- and community-based interventions demonstrates that psychoeducation and cognitive stimulation programmes can significantly reduce load and distress. Despite this, caregiver support remains limited to a small number of NGOs concentrated in urban areas, with no national respite or carer-focused policy framework, leaving families to absorb the social, emotional, and economic costs of dementia care largely on their own.

The EAS serves as the central anchor for carer education, peer support groups, training workshops, public awareness campaigns, and dementia-friendly community activities. These initiatives provide practical coping strategies, reduce stigma, and offer informal care navigation in a system where formal coordination remains limited. Additional grassroots and professional initiatives, such as the Dementia Support Initiative in Egypt, contribute advocacy, training, and professional awareness, particularly among healthcare workers and social care actors.

However, there are no clearly defined national cash benefits or carer allowances specifically targeted to dementia, and social protection measures remain fragmented.

Egypt does not currently have a stand-alone, dementia-specific national strategy or action plan. Instead, dementia policy is embedded implicitly within broader health-system reform, as in the Universal Health Insurance Law No. 2/2018, which serves as the principal structural platform for expanding access to diagnosis and specialist care.

The UHI reform introduces mandatory population coverage, purchaser–provider separation, standardised benefit packages, and strengthened primary-care gatekeeping, all of which are indirectly relevant to dementia. However, because dementia is not yet articulated as a discrete policy priority, there is no nationally defined dementia pathway, post-diagnostic support framework, or dedicated funding stream, leaving implementation uneven and highly dependent on university hospitals and NGO activity.

At the systems level, the EDN registry represents a major methodological innovation by enabling standardised data collection across centers, supporting longitudinal analysis and policy-relevant insights. In parallel, the Davos Alzheimer’s Collaborative (DAC)–American University in Cairo (AUC)–University College London (UCL) collaboration emphasises scalable early-detection approaches, workforce training, and preparation for future biomarker integration, positioning Egypt to engage with next-generation diagnostic paradigms as they become clinically actionable.

An exploratory laboratory study examined plants used in Egyptian traditional medicine for memory complaints, assessing their activity in Alzheimer’s disease–relevant in vitro assays. Extracts were tested for acetylcholinesterase (AChE) inhibition, COX-1 inhibition, and antioxidant effects. Adhatoda vasica and Peganum harmala showed AChE inhibition under laboratory conditions; Ferula assafoetida demonstrated COX-1 inhibition; and Terminalia chebula, T. arjuna, and Emblica officinalis exhibited antioxidant activity. These findings reflect early-stage, preclinical results only. They do not demonstrate clinical effectiveness or safety in humans, and further research would be required before considering any therapeutic application.